EUCTR2005-005507-41-GB进行中（未招募）1 期
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •To be eligible for this trial, patients must have documentation of the following:
- •Age >=18 years
- •Body weight >= 85 kg
- •Serologic evidence of CHC infection by an anti-HCV antibody test (current or historical)
- •Evidence of hepatitis C genotype 1 infection by molecular assay
- •Serum HCV RNA quantifiable at >= 400,000 IU/mL by the Roche TaqMan HCV Test
- •Chronic liver disease consistent with CHC infection on a biopsy obtained within the past 24 calendar months as judged by a central pathologist. For patients with incomplete/transition to cirrhosis or cirrhosis, a biopsy within 36 calendar months before the first dose is sufficient. A maximum of 20% of patients with cirrhosis or incomplete/transition to cirrhosis will be permitted to enroll in the trial.
- •Patients with cirrhosis or incomplete/transition to cirrhosis must have an abdominal ultrasound, computerized tomographic (CT) scan, or magnetic resonance imaging (MRI) scan without evidence of hepatocellular carcinoma (within 2 months prior to randomization) and a serum alpha-fetoprotein (AFP) <100 ng/mL
- •Compensated liver disease (Child-Pugh Grade A clinical classification only)
- •Negative urine pregnancy test result (for females of childbearing potential) documented within the 24-hour period prior to the first dose of study drugs. Additionally, all female patients of childbearing potential and all males with female partners of childbearing potential must use two forms of effective contraception (combined) during treatment and 6 months after treatment end
- •Willingness to give written informed consent and willingness to participate in and comply with the study requiremen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with any of the following will not be eligible for participation:
- •Infection with HCV genotype 1 mixed with a genotype other than genotype 2 or genotype 3 or infection with an indeterminate genotype. Patients with indeterminate or mixed genotype 1 subtypes will be allowed.
- •History of having received interferon alpha (IFN), PEG-IFN, ribavirin, viramidine, levovirin, or investigational HCV protease or polymerase inhibitors at any previous time, or any other systemic antiviral therapy with established or perceived activity against the hepatitis C virus =<3 months prior to the first dose of study drug
- •History of having received any investigational drug =< 3 months prior to the first dose of study drug or the expectation that such drugs will be used during the study. Patients enrolled in this study cannot be enrolled in another study for either research, diagnostic or treatment purposes.
- •Patients who are expected to need systemic antiviral therapy with established or perceived activity against HCV at any time during their participation in the study are also excluded
- •Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, or anti-HIV Ab • History or other evidence of a medical condition associated with chronic liver disease other than CHC (eg, hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures) • Females who are pregnant or breast-feeding
- •Male partners of females who are pregnant
- •Absolute neutrophil count (ANC) <1500 cells/mm3
- •Platelet count <90,000 cells/mm3
- •Hemoglobin concentration <12 g/dL in females or <13 g/dL in males or any patient with a baseline increased risk for anemia (eg, thalassemia, sickle cell anemia, spherocytosis, history of gastrointestinal bleeding) or for whom anemia would be medically problematic
- •Serum creatinine concentration >1.5 times the upper limit of normal at screening
- •The use of colony stimulating factors such as granulocyte colony stimulating factor (G-CSF), erythropoetin or other therapeutic agents to elevate hematology arameters to facilitate patient entry into the study
- •History of severe psychiatric disease, including psychosis and/or depression, characterized by a suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of psychiatric disease
- •Beck Depression Inventory (BDI) score of >= 20
- •History of immunologically mediated disease (eg, inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis (defined as affecting >10% of the body, here the palm of one hand equals 1%, or if the hands and feet are affected), rheumatoid arthritis requiring more than intermittent nonsteroidal anti-inflammatory medications for management
- •History or other evidence of decompensated liver disease or a Child-Pugh score >6. Coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices are conditions consistent with decompensated liver disease
- •History or other evidence of chronic pulmonary disease associated with functional limitation
- •History of severe cardia
研究者
相似试验
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kggenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-HUF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-NLF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
1 期
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infectionMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-FRF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-DEF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-SEF. Hoffmann-La Roche Ltd1,140